Testosterone & Tamoxifen Trial (T&T)
T&T Trial: Adding Testosterone to Tamoxifen in Male Breast Cancer Patients
Sponsor: University Medical Center Groningen
Terminated
Five patients were included; it did not succeed in recruiting the target number of 6 patients. This is as a result of the rarity of this disease in men.
Other terminated trials from University Medical Center Groningen
- Metastatic Solid Tumor · Phase NA · Nov 2024
- Diabetes Mellitus, Type 2 · Jul 2024
- ARDS · Phase PHASE4 · May 2024
- Esophageal Cancer · Phase NA · Sep 2023
- Esophageal Cancer · Phase PHASE1 · Oct 2022
See all terminations from University Medical Center Groningen
Listed as NCT05156606, this NA trial focuses on Male Breast Cancer and remains terminated or withdrawn. Sponsored by University Medical Center Groningen, it has been updated 9 times since 2022, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Terminated NA
Status: Active Not Recruiting → Terminated
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting NA
-
Jun 2024 — Jul 2024 [monthly]
Active Not Recruiting NA
-
May 2024 — Jun 2024 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
-
Nov 2023 — May 2024 [monthly]
Recruiting NA
▶ Show 4 earlier versions
-
Dec 2022 — Nov 2023 [monthly]
Recruiting NA
-
Nov 2022 — Dec 2022 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
-
Jun 2022 — Nov 2022 [monthly]
Not Yet Recruiting NA
-
Jan 2022 — Jun 2022 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- University Medical Center Groningen
For direct contact, visit the study record on ClinicalTrials.gov .